FDA Investigator Michelle D Haamid

Michelle D Haamid has conducted inspections on 294 sites in 4 countries as of 28 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
294
Last Inspection Date:
28 May 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, India, Germany, Portugal
FDA Investigators that have inspected at least one site in common with Michelle D Haamid:
Adam R Cooke, Alan P Kurtzberg, Alberto A Viciedo, Allen F Hall, Althea A Williams, Amanda L Evanco, Amy H Ruble, Angela Shepas, Anthony J Grace, April R Bowen, Babatunde D Babalola, Barbara M Frazier, Betsy C Galliher, Billy M Battles, Bonita S Chester, Brandy D Brown, Brentley S Collins, Brian A Graves, Candido Torres, Cara M Minelli, Carl E Lovrich, Carol F Robinson, CDR Rochelle B Young, RPh, MSA, CDR Sean T Creighton, CDR Thomas R Berry, PPh, Charanjeet Jassal, Chateryl K Washington, Cheryl A Grandinetti, Cheryl D Barton, Christie B Rice, Christine M O'leary, Christopher B May, Claudele S Razo, Claudette D Brooks, Cordelia J Brammer, Courtney A Gilbert, Craig A Garmendia, Cress S Hall, Cynthia A Harris, MD, RN, Cynthia F Kleppinger, MD, Darcy E Brillhart, David E Lowe, Dawn M Braswell, Debra J Tucker, Dellarese L Herbert, Derek C Price, Devaughn Edwards, Dolores Harper, Doretha M Tonkins, Doretha M Wilson, Dr. Robert C Horan, MD, Dr. Sriram Subramaniam, PhD, Edecia A Richards, Edward Deberry, Eileen J Bannerman, Ernest H Blackwood, Esra Toussaint, Felix Maldonado, Gabriel R Mclemore, Gamal A Norton, Gary E Coleman, Jr, REHS, Gerald N Mcgirl, DDS, Heather Akleimola Hulbert, Heather M Wheeler, Helen R Bester, Hristu B Chepa, Inga M Warr, Jacqueline D Mitchell, James C Maclaughlin, James I Giefer, James P Lewis, Jr, Jared P Stevens, Jawaid Hamid, Jessica A Stephens, Jessica Fields, Joe A Odom, John D White, Jonathan A Ferguson, Jorge F Christian, Jorge L Gonzalez, Joseph F Owens, June P Page, Justin A Boyd, Karen A Coleman, Kassa Ayalew, MD, Kathleen D Culver, Kenneth L Smalls, Kevin D Kallander, Kimberly Cdelk Brooks, Kip J Hanks, Kristen E Rescigno, Lareese K Thomas, Latorie S Jones, Laureen F Kononen, Lauren L Vajo, Lawrence Thomas, Leon L Crawley, Leslie W Gilbert, Libia M Lugo, Lillie D Witcher, Luckner Jean Marie, Mancia R Walker, Marcia A Worley, Marla A Cassidy, Mary Alice Papadimitriou, Mary T Carden, Matthew B Casale, Melanie W Pishnery, Metitia G Sanders, Metitia M Gramby, Miaja Umaedi, Michael A Charles, Michael F Skelly, PhD, Morrell, Myla D Chapman, Nicholas M Smith, Nicole M Bell, Nigel L Hirth, Noreen Muñiz, Omotunde O Osunsanmi, Pamela L Velez Vega, Patricia F Hudson, Paul A Bonneau, Paul W Moy, Paula J Bretz, Perry H Gambrell, Philip F Istafanos, DMV, MS, Prabhu P Raju, Randy D Baxter, Randy L Clarida, Rashonda N Rucker, Reba A Gates, Richard J Bashay, Richard L Bartlett, Richard L Garcia, Robert Jennings, Robin N Goins, Rose Xu, Russell R Zablan, Saeid E Kazan, Samuel L Murray, Sayeeda Hdabe, Scott B Laufenberg, Seneca D Toms, Sereen Gmorgan Murray, Shelley H Beausoleil, Sheri S Oliver, Sondra M Rates, Sonya M Edmonds, Srinivas R Chennamaneni, PhD, Sripal R Mada, PhD, Stardust W Mazzariello, Stephanie Mangigian, MS/OSH, RN, Steven D Banks, Tajah L Blackburn, Torrance J Slayton, Traci M Armand, Tracy R Ball, Trang N Cox, Travis S Bradley, Valerie Jgrecek Trinh, Vanessa E Coulter, Vicky C Stoakes, Victoria Hampshire, Vincent M Williams, Viviana Matta, Wayne D Mcgrath, William P Tonkins

Michelle D Haamid's Documents

Publish Date Document Type Title
May, 2013 FDA 483 Steven Rohrbeck - Form 483, 2013-05-06
June, 2009 EIR GlaxoSmithKline - EIR, 2009-06-11
March, 2003 EIR Professional Lab & Research - EIR, 2003-03-28
September, 2003 EIR Idexx Pharmaceuticals Inc - EIR, 2003-09-04
April, 2001 EIR John Burkart, MD - EIR, 2001-04-12
July, 2001 FDA 483 Catalent Pharma Solutions, LLC - Form 483, 2001-07-27
February, 2000 EIR Dean, Christine Joan MD - EIR, 2000-02-08
April, 2002 EIR Family Health International - EIR, 2002-04-02
February, 2011 EIR Duke University Health System Irb - EIR, 2011-02-04
September, 2002 EIR Miracles in Sight - EIR, 2002-09-18
November, 2007 EIR Idexx Pharmaceuticals Inc - EIR, 2007-11-14
April, 2002 FDA 483 Kizito Inc - Form 483, 2002-04-02
March, 2004 FDA 483 Grifols Therapeutics Inc. - Form 483, 2004-03-25
January, 2003 EIR Laboratory Corp Of America - EIR, 2003-01-28
January, 2004 FDA 483 Novartis Animal Health US Inc - Form 483, 2004-01-23
July, 2001 EIR Catalent Pharma Solutions, LLC - EIR, 2001-07-27
October, 2003 EIR Ginger Williams, DVM - EIR, 2003-10-09
January, 2005 FDA 483 Charter Medical LLC - Form 483, 2005-01-25
January, 2001 EIR Abbott Laboratories - EIR, 2001-01-11
January, 2001 EIR Crouse, John R. MD - EIR, 2001-01-30
January, 2001 FDA 483 Wake Forest University School of Medicine - Form 483, 2001-01-30
March, 2004 EIR Bayer AG - EIR, 2004-03-25
October, 2002 EIR Professional Lab & Research - EIR, 2002-10-16
March, 2001 EIR Laboratory Corp Of America - EIR, 2001-03-06
April, 2002 EIR Ward, Walter, A., Dr. - EIR, 2002-04-29
June, 2000 EIR Arnold, Gordon, Dr. - EIR, 2000-06-23
February, 2000 EIR Kitzman, Dalane, W. MD - EIR, 2000-02-18
May, 2009 FDA 483 Joseph O Moore MD - Form 483, 2009-05-06
October, 2000 EIR Roberts, Lynn - EIR, 2000-10-18
February, 2000 FDA 483 Epilepsy Institute of NC - Form 483, 2000-02-08
January, 2003 FDA 483 Laboratory Corp Of America - Form 483, 2003-01-28
May, 2013 EIR Steven Rohrbeck - EIR, 2013-05-06

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more